VNAR development through antigen immunization of Japanese topeshark (Hemitriakis japanica) [PDF]
Frontiers in Bioengineering and Biotechnology, 2023 The VNAR (Variable New Antigen Receptor) is the smallest single-domain antibody derived from the variable domain of IgNAR of cartilaginous fishes. Despite its biomedical and diagnostic potential, research on VNAR has been limited due to the difficulties ...
Tatsuhiko Ozawa +2 more
exaly +6 more sources
The influence of antibody humanization on shark variable domain (VNAR) binding site ensembles [PDF]
Frontiers in Immunology, 2022 Sharks and other cartilaginous fish produce new antigen receptor (IgNAR) antibodies, as key part of their humoral immune response and are the phylogenetically oldest living organisms that possess an immunoglobulin (Ig)-based adaptive immune system. IgNAR
Klaus Liedl +2 more
exaly +6 more sources
Construction and application of a large capacity VNAR library from the whitespotted bamboo shark (Chiloscyllium playgiosum) [PDF]
Acta Pharmaceutica Sinica BFifty whitespotted bamboo sharks (Chiloscyllium playgiosum) of both sexes were used to establish a large capacity variable domain of the new antigen receptor (VNAR) library with a total capacity of over 109 colony-forming units (CFU).
Ming-Wei Wang +2 more
exaly +6 more sources
Intraocular Penetration of a vNAR: In Vivo and In Vitro VEGF165 Neutralization [PDF]
Marine Drugs, 2018 Variable new antigen receptor domain (vNAR) antibodies are novel, naturally occurring antibodies that can be isolated from naïve, immune or synthetic shark libraries. These molecules are very interesting to the biotechnology and pharmaceutical industries
Camacho-Villegas Tanya +2 more
exaly +5 more sources
Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR [PDF]
Pharmaceutics, 2020 Passive immunotherapy, i.e., treatment with therapeutic antibodies, has been increasingly used over the last decade in several diseases such as cancers or inflammation.
Pierre Lafaye, Lafaye Pierre
exaly +6 more sources
Allosteric inhibition of Aurora-A kinase by a synthetic vNAR domain [PDF]
Open Biology, 2016 The vast majority of clinically approved protein kinase inhibitors target the ATP-binding pocket directly. Consequently, many inhibitors have broad selectivity profiles and most have significant off-target effects.
Selena G. Burgess +6 more
doaj +5 more sources
Frontiers in Marine Science, 2023 Elasmobranchs are crucial for comparative studies of evolution, as they belong to the most ancient vertebrate lineages that survived numerous extinction events and persist until today.
Jianqing Wen +14 more
exaly +3 more sources
Identification and characterization of shark VNARs targeting the Helicobacter pylori adhesin HpaA
Artificial Cells, Nanomedicine, and Biotechnology, 2023 Helicobacter pylori (H. pylori) is recognized as a pathogen associated with several gastrointestinal diseases. The current treatments exhibit numerous drawbacks, including antibiotic resistance. H.
Yanchun Gao +7 more
doaj +3 more sources
Screening and characterization of inhibitory vNAR targeting nanodisc-assembled influenza M2 proteins
iScience, 2023 Summary: Influenza A virus poses a constant challenge to human health. The highly conserved influenza matrix-2 (M2) protein is an attractive target for the development of a universal antibody-based drug.
Chuandi Yu +26 more
doaj +3 more sources
Molecular Therapy - Oncolytics, 2022 Chimeric antigen receptor (CAR)-T cell therapy shows excellent potency against hematological malignancies, but it remains challenging to treat solid tumors, mainly because of a lack of appropriate antigenic targets and an immunosuppressive tumor ...
Chi-Ping Day +2 more
exaly +3 more sources